Besides the immunomodulators (IMM) such as azathioprine (AZA) and methotrexate (MTX) and the first biologic agents with anti-TNFα action, in the last few years, some new selective molecules have been introduced in the therapeutic scenario of IBD, such as vedolizumab (VDZ) and ustekinumab (USK). The gene discussed is TNF; the disease is inflammatory bowel disease.